Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
GS030
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
06 Feb 2021 - 07 Feb 2021
44th Annual Macula Society Meeting – Virtual
04 February 2021
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non Human Primates
13 Nov 2020 - 15 Nov 2020
American Academy of Ophthalmology 2020 – Virtual
02 Oct 2020 - 04 Oct 2020
EURETINA 2020 – Virtual
24 Jul 2020 - 26 Jul 2020
2020 Annual Scientific Meeting ASRS – Virtual format
03 May 2020 - 07 May 2020
2020 ARVO Annual Meeting, Baltimore (MD), US – cancelled
21 April 2020
GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update
14 April 2020
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa
06 April 2020
GenSight Biologics Provides Update on Operations in the Context of COVID-19
15 Apr 2020 - 17 Apr 2020
2020 Cell & Gene Meeting on the Mediterranean, Barcelona, Spain – cancelled
View previous 9 articles
1
2
3
4
5
6
View next 9 articles
Go back to the page of the page